TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
+21.98%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$679M
AUM Growth
+$679M
(+1.2%)
Cap. Flow
-$52.2M
Cap. Flow
% of AUM
-7.69%
Top 10 Holdings %
Top 10 Hldgs %
38.68%
Holding
124
New
21
Increased
24
Reduced
16
Closed
25
Top Buys
| 1 |
InflaRx
IFRX
|
$12.9M |
| 2 |
Verastem
VSTM
|
$8.48M |
| 3 |
Atea Pharmaceuticals
AVIR
|
$7.57M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
$5.98M |
| 5 |
ADMA Biologics
ADMA
|
$4.65M |
Top Sells
| 1 |
Novo Nordisk
NVO
|
$21.5M |
| 2 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
$9.81M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$9.01M |
| 4 |
BLUE
bluebird bio
BLUE
|
$8.23M |
| 5 |
Moderna
MRNA
|
$7.29M |
Sector Composition
| 1 | Healthcare | 92.72% |
| 2 | Financials | 6.8% |
| 3 | Real Estate | 0.3% |
| 4 | Consumer Discretionary | 0.15% |
| 5 | Utilities | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Capital One
COF
$142B
| $8.75M | 1.29% |
80,000
-20,000
| -20% | -$2.19M |
|
|
THRD
27
DELISTED
Third Harmonic Bio
THRD
| $8.66M | 1.27% |
1,800,000
| – | – |
|
|
28
Verastem
VSTM
$585M
| $8.48M | 1.25% |
+1,140,000
| New | +$8.48M |
|
|
AMRN
29
Amarin Corp
AMRN
$311M
| $8.45M | 1.24% |
355,000
+85,000
| +31% | +$2.02M |
|
30
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $8.45M | 1.24% |
600,000
| – | – |
|
31
Ionis Pharmaceuticals
IONS
$9.64B
| $8.21M | 1.21% |
200,000
| – | – |
|
|
ELEV
32
DELISTED
Elevation Oncology
ELEV
| $6.08M | 0.9% |
4,000,000
+2,600,000
| +186% | +$3.95M |
|
33
Bio-Rad Laboratories Class A
BIO
$7.8B
| $6.07M | 0.89% |
16,000
| – | – |
|
34
Adicet Bio
ACET
$60.8M
| $6.03M | 0.89% |
2,479,552
-40,448
| -2% | -$98.3K |
|
35
Quince Therapeutics
QNCX
$86.5M
| $5.44M | 0.8% |
3,613,280
-6,720
| -0.2% | -$10.1K |
|
|
LENZ
36
LENZ Therapeutics
LENZ
$1.12B
| $5.42M | 0.8% |
297,946
+8,165
| +3% | +$149K |
|
37
Cullinan Oncology
CGEM
$456M
| $4.84M | 0.71% |
450,000
-50,000
| -10% | -$538K |
|
|
38
ADMA Biologics
ADMA
$4.03B
| $4.65M | 0.68% |
+1,260,000
| New | +$4.65M |
|
39
Citigroup
C
$175B
| $4.6M | 0.68% |
100,000
| – | – |
|
40
Dianthus Therapeutics
DNTH
$781M
| $4.59M | 0.68% |
378,750
+625
| +0.2% | +$7.58K |
|
41
Pyxis Oncology
PYXS
$91.2M
| $4.58M | 0.67% |
1,787,775
-693,887
| -28% | -$1.78M |
|
|
ADAP
42
Adaptimmune Therapeutics
ADAP
$13.9M
| $4.52M | 0.67% |
+4,887,238
| New | +$4.52M |
|
|
RAIN
43
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $4.49M | 0.66% |
+3,740,341
| New | +$4.49M |
|
|
GNFT
44
Genfit
GNFT
$198M
| $4.37M | 0.64% |
1,234,436
+21,921
| +2% | +$77.6K |
|
45
Bolt Biotherapeutics
BOLT
$9.29M
| $4.27M | 0.63% |
166,690
+85,312
| +105% | +$2.18M |
|
|
ENZ
46
DELISTED
Enzo Biochem, Inc.
ENZ
| $4.23M | 0.62% |
2,300,000
| – | – |
|
47
NovoCure
NVCR
$1.35B
| $4.15M | 0.61% |
+100,000
| New | +$4.15M |
|
|
ASLN
48
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| $4.12M | 0.61% |
141,009
-4,654
| -3% | -$136K |
|
49
Dynavax Technologies
DVAX
$1.19B
| $3.88M | 0.57% |
300,000
| – | – |
|
50
Veritex Holdings
VBTX
$1.86B
| $3.77M | 0.55% |
210,000
+100,000
| +91% | +$1.79M |
|